

Table 1 Characteristics of included studies.

Authors	country	Study design	Patients(n)	Mean age(SD)(years)	Type of ANC	Name of the vaccine	COVID-19 vaccine dosa(n)			Follow up days
							D1	D2	D3	
Anat Achiron	Israel	observational study	555		MS	mRNA vaccine	555	435		67
Mohammad Ali Sahraian	Iranian	observational study	579		MS	inactivated vaccines	579	350		21
Farren Basil Shaw Briggs		Retrospective, observational study	719	53.0 (11.8)	MS	mix	719	459		90
Jenna A	US	observational study	292	50.4 (12.4)	MS	mix				28
Fioravante Capone	Italy	Prospective, observational study	140	43.5 (12.7)	MS	mRNA vaccine	140	140		60
Ethel Ciampi	Chile	Multicentric, prospective, observational study	178	39.7 (11.2)	MS	mix	178			210
John R. Ciotti	US	prospective, observational, study	201		MS	mRNA vaccine	201			240
Massimiliano Di Filippo	Italy	Multicentric, prospective, observational study	324	42.7(10.8)	MS	mRNA vaccine	324	322		60
Alessandro Dinoto	Italy	Multicentric, Retrospective, observational study	26		MS	mRNA vaccine	26	26		
Alon Doron	Israel	observational study	150	57.2 ( 18)	NMOSD	mRNA vaccine	150	147	133	42
Sapir Dreyer-Alster	Israel	prospective, observational, study	211		MG	mRNA vaccine			211	66
Masoud Etemadifar	Iran	Retrospective, observational study	517	37.81 (8.74)	MS	inactivated vaccines	517	417		
Antonio Farina	Italy	observational study	104		MS	mRNA vaccine	104	98	63	60
Josep Gamez MD	Spain	prospective, observational, study	91		MG	mRNA vaccine	91	89		225
Maria Pia Giannoccaro	Italy	longitudinal observational	291		MS/ MG	mRNA vaccine	300	300		

		study									
Vanja Jovicevic	Serbia	observational study	9	54.3( 10.3 )	NMOSD	mix		9			
Trinchillo, A.	Italy	Retrospective, observational study	113	58.4(15.5)	MG	mRNA vaccine			113	360	
Stastna, D.	USA	Retrospective, observational study	1678		MS/ NMOSD	mix	166 1			90	
Reyes-Leiva, D.	USA	Retrospective, observational study	100	55.85 (15.48)	MG	mRNA vaccine	100	100		90	
Rauber, S.	Germany	Retrospective, observational study	59		MS	mix		59		28	
Pincheira, A. U.	Australia	Retrospective observational study	200	64.3 (13.9)	MG	mix		200		14	
Peric, S.	Serbia	cross-sectional study	125	61.7(16.9)	MG	mix	87			365	
Mariottini, A.	Italy	monocentric retrospective observational study	120		MS	mix				≥30	
Maniscalco, G.T	Italy	Retrospective, observational study	310		MS	mRNA vaccine	310	288		180	
Lotan, I.	Italy	Retrospective, observational study	55		MG	mRNA vaccine	55	51		168	
Li, H. Y	China	Retrospective, observational study	107	45.68 (1.49)	MG	inactivated vaccines	107	97	35	28	
Kong, L.	China	Retrospective, observational study	187		MS/ NMOSD					90	
Kavosh, A	Iran	cross-sectional study	1538	40.45( 9.7 4)	MS	inactivated vaccines	153 8	153 8			